| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 67 | 36.5x | 17.8x | Top tier | |
Growth | 13 | -0.2% | 7.1% | Bottom tier | |
Quality | 83 | 10.6% | 4.5% | Top tier | |
Safety | 61 | 2.5x | 2.6x | Around median | |
Capital Return | 60 | 6.20% | 2.12% | Around median | |
Momentum | 70 | 10.2% | 2.9% | Top tier | |
Sentiment | 85 | 15 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Pfizer Inc. is a biopharmaceutical company that generates revenue from a portfolio of medicines and vaccines spanning oncology, vaccines, primary care, immunology, and inflammation. Its cited commercial drivers include Eliquis, Padcev, the Vyndaqel family, Lorbrena, and NURTEC, alongside the COVID-19 products COMIRNATY and Paxlovid; the Seagen, Metsera, and Biohaven transactions also added platforms and portfolios in oncology, obesity, and migraine. The company reinvests part of its cash flows in research and development, having spent $5.5 billion on internal and external research and development during the first half of fiscal 2026, versus $4.9 billion returned to shareholders through quarterly dividends.
In quarter 2 of fiscal 2026, revenue totaled $15.0 billion, up 1% operationally year over year, while the business excluding COVID-19 products grew 5% operationally. Launched and acquired products generated $3.2 billion in revenue and grew 18% operationally, or 27% after excluding nonrecurring items in the comparable quarter; revenue from acquired products also grew 25% operationally after the same exclusion. Gross profit under EDGAR was approximately $10.9 billion, equivalent to a gross margin of about 72.7%, while adjusted gross margin was 76% and adjusted operating margin was 35%.
Pfizer recorded an EDGAR net loss of $248 million and a reported loss of $0.04 per share in quarter 2 of fiscal 2026, versus adjusted earnings per share of $0.77, exceeding the $0.68 estimate. The large divergence between the two results was due to $4.3 billion of non-cash intangible asset impairments, primarily related to the outcome of the phase 3 SV study in lung cancer and, to a lesser extent, the removal of Oxbryta revenue projections following discussions with FDA. On a trailing-twelve-month basis ending in 2026, revenue was $63.7 billion, gross profit was $46.6 billion, and net income was $4.3 billion.
The analyst consensus on PFE is “Neutral,” with an average price target of $28.17 and a range of $26 to $31; the average is below the annual high of $28.75, while the highest target exceeds that high, within a 52-week range of $23.58–$28.75. No published price-to-earnings ratio is available in the data, which is consistent with the distortion in reported earnings caused by $4.3 billion of non-cash impairments in quarter 2 of fiscal 2026, so the valuation assessment depends more heavily on execution against adjusted earnings-per-share guidance of $2.80–$3.00 and the pipeline's conversion into revenue after 2028.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
Pfizer recorded an EDGAR net loss of $248 million and a reported loss of $0.04 per share in quarter 2 of fiscal 2026. In contrast, adjusted earnings per share were $0.77, exceeding the analyst estimate of $0.68. The difference was primarily due to $4.3 billion of non-cash impairments related to the outcome of the SV study in lung cancer and, to a lesser extent, the removal of Oxbryta revenue projections following discussions with FDA.
The company raised its revenue range to $60.5–$62.5 billion after the non-COVID-19 portfolio outperformed its expectations in the first half of fiscal 2026. This portfolio grew 5% operationally in quarter 2 of fiscal 2026, while launched and acquired products generated $3.2 billion in revenue and grew 18% operationally. The improvement came from several products, including Eliquis, NURTEC, and Padcev, despite lowering the COVID-19 product revenue forecast to approximately $4 billion.
The legacy Seagen portfolio in the United States grew 21% year over year in quarter 2 of fiscal 2026 after excluding a nonrecurring stocking benefit. Padcev grew by more than 20%, and its share of new patients with locally advanced or metastatic urothelial cancer exceeded 60%. FDA also expanded the use of Padcev with pembrolizumab in muscle-invasive bladder cancer based on data showing a 35% reduction in the risk of death, and Pfizer initiated an additional phase 3 study in bladder-preserving therapy.
Automated analysis for informational purposes only — not investment advice.
Pfizer is targeting the first approval for berobenatide in 2028, so the asset remains in the clinical investment stage during fiscal 2026. The monthly 4.8 mg dose showed a placebo-adjusted weight reduction of up to 12.3% over 28 weeks, while the high dose achieved an average reduction of approximately 16% over 32 weeks. As of August 4, 2026, three phase 3 studies were underway, with a plan to advance ten phase 3 studies during fiscal 2026.
Pfizer lowered its COVID-19 product revenue forecast to approximately $4 billion from $5 billion because of lower infection levels. Management explained that Paxlovid use is directly linked to the number of infections, while COMIRNATY vaccine sales are relatively more stable and the majority of its expected sales depend on the vaccination season near the end of fiscal 2026. Growth in the non-COVID-19 portfolio offset this weakness in the first half of fiscal 2026, but it does not eliminate future volatility in Paxlovid revenue.
Pfizer is targeting total net savings of approximately $9.7 billion through the end of 2029 through productivity and manufacturing optimization programs. The company expects to achieve most of the $7.2 billion in core savings by the end of 2026, followed by an additional $2.5 billion during 2027–2029. In quarter 2 of fiscal 2026, it achieved $175 million in savings from the first phase of manufacturing optimization, against an annual target of $700 million.
